Replies to post #249417 on Biotech Values

[DewDiligence]

TRML—(-36%)—suffers collateral damage_from Roche’s Enspryng trial:

https://www.fiercepharma.com/pharma/despite-positive-trial-roche-says-enspryng-fell-short-expectations-myasthenia-gravis

TRML’s TOUR006 has the same anti-IL-6 MoA as Enspryng.

TRML is the result of a 2023 reverse-merger (#msg-173043164).